- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Unresectable locally advanced (Stage III) non-small cell lung cancer
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Osimertinib – July 2025
Osimertinib; Tablet 40 mg, Tablet 80 mg; Tagrisso®
Last updated
9 July 2025